Sep 8, 2026, 3:43 PM6 views

Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback

Novartis saw a treatment for a rare muscle-wasting disease fail a late-stage study, the third clinical-trial setback in a week. The medicine was the centerpiece of Novartis’s $12 billion.

Business

Bloomberg Verified Source

Syndicated via official news feed

Read Full Story on Bloomberg

Explore all Business stories

Syndicated feed content with full publisher credit.

Business Desk

More in Business

Continue reading verified coverage and related developments on this desk.

View All

BUSINESS12M AGO

Meta stock jumps as new personal AI agent Muse addresses a major investor concern

Meta’s Muse could be the beginning of a product cycle that the market has not yet priced into the stock, an analyst says.

BUSINESS14M AGO

Canadian Oil Merger Spotlights Alberta Boom

Tamarack’s deal to take over Headwater shows the increasing appeal of the Clearwater play.

BUSINESS27M AGO

Wall Street’s Leveraged ETF Push Gets New Twist With Hourly Bets

A corner of the ETF market drawing regulatory scrutiny is pushing for still shorter-term speculation.

BUSINESS28M AGO

Brent Hits $100, US Slaps Bans, New Tariffs on Canada, Trump to Speak at RNC

Brent crude reaches $100 a barrel for the first time since July as the US and Iran keep up attacks on each other. Trade tensions escalate as the Trump administration blocks imports of some.

BUSINESS30M AGO

Bessent bond plan details to be revealed as Treasury secretary warns FX traders he's 'the house now'

The department is expected to announce around 11 a.m. the size of a buyback operation it announced Aug. 19.

BUSINESS31M AGO

How To Stay Nourished On A College Meal Plan: A Doctor’s Perspective

College freshmen encounter campus food environments mirroring America's. Students often prioritize taste over nutrition, despite healthier alternatives being available.